News Center

– Data provide additional evidence supporting development of praliciguat as a potential treatment for diabetic nephropathy and for heart failure with preserved ejection fraction – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 23, 2018-- Ironwood Pharmaceuticals, Inc.

– Program Designed to Support U.S. Regulatory Filing of IW-3718 as Potential Treatment for Patients Who Continue to Suffer From GERD Despite Receiving Standard of Care – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 21, 2018-- Ironwood Pharmaceuticals, Inc.

- Praliciguat Phase IIa data to be featured in an oral presentation - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 20, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced that the company will present clinical and preclinical data for the company’s

– Olinciguat Phase II trial in sickle cell disease continues to enroll patients – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 7, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Orphan